Substance / Medication

Romiplostim

Overview

Active Ingredient
romiplostim
RxNorm CUI
805452
Labeler: Amgen, IncUpdated: 2025-03-13T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review.
He Xin, Ran Ningyuan, Wang Ting et al. · Medicine (Baltimore) · 2022
PMID: 36550870Meta-AnalysisFull text (PMC)
Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis.
Meng Fanqiao, Chen Xiuqiong, Yu Shunjie et al. · Front Oncol · 2020
PMID: 33324559Meta-AnalysisFull text (PMC)
Efficacy of romiplostim in the treatment of ITP in children: a meta-analysis.
Li H, Yang H, Liu W-J · Eur Rev Med Pharmacol Sci · 2018
PMID: 30280805Meta-Analysis
[Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France].
Chiche L, Perrin A, Stern L et al. · Transfus Clin Biol · 2014
PMID: 24797790Meta-Analysis
The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Deuson Robert, Danese Mark, Mathias Susan D et al. · J Med Econ · 2012
PMID: 22533524Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Romiplostim (substance)
SNOMED CT
439122000
UMLS CUI
C2364481
RxNorm CUI
805452
Labeler
Amgen, Inc

Clinical Data

This intervention maps to 0 entities in the Healos knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.